Solid Tumors
Pediatric patients with solid tumors studied for maximum tolerated dose of irofulven
Published in Blood Weekly, September 7th, 2006
"We performed a Phase I trial of irofulven to determine the MTD, the dose-limiting toxicity (DLT), and the plasma pharmacokinetics of irofulven in children {{<=}}21 years of age with refractory/recurrent malignancies. Thirty-five patients were entered into the study, of whom 34 were eligible," researchers in the United States reported.
"Patients received irofulven daily x 5 days every 28 days over 10 min, following pre-treatment with ondansetron (0.45 mg/kg) and dexamethasone (12 mg/m2). The initial dose of irofulven...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-09-07)
More Articles from Blood Weekly
- Blood Banking
SYTO 16 dye detects apoptotic lymphocytes and CD34+ cells in cryopreserved cord blood - Blood Safety
Filter modifications reduce risk of transfusion-transmitted prion disease - Tissue Engineering
Autologous human tissue-engineered heart valves developed - Tissue Engineering
Heart valve allografts remodel and grow accordingly to somatic growth of child - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - Adipose Tissue
Adipose tissue could be a good source of cells for short-term hematopoiesis reconstitution - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
